Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

H Gogas,B Dréno,J Larkin,L Demidov,D Stroyakovskiy,Z Eroglu,P Francesco Ferrucci,J Pigozzo,P Rutkowski,J Mackiewicz,I Rooney,A Voulgari,S Troutman, B Pitcher,Y Guo,Y Yan,M Castro,S Mulla,K Flaherty,A Arance

Annals of Oncology（2021）

引用 65|浏览83

暂无评分

摘要

•Cobimetinib plus atezolizumab did not improve PFS versus pembrolizumab monotherapy in BRAFV600 wild-type advanced melanoma.•Results were consistent across prespecified subgroups according to known prognostic factors.•Higher tumor mutational burden was associated with improved clinical outcomes in both treatment arms.•As expected, the combination was associated with a higher incidence of AEs than pembrolizumab monotherapy.

查看译文

关键词

atezolizumab,cobimetinib,pembrolizumab,melanoma,BRAF wild-type

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要